Silver Book

Silver Book Fact

“If you had been diagnosed with chronic myeloid leukemia (CML) in 1999, chances were that you would not be alive today. Just 3 out of 10 patients survived for even five years. In the meantime, you had two daunting treatment options: a high-risk bone marrow transplant or daily injections of interferon, the side effects of which have been compared to ‘having a bad case of the flu every day of your life.'”

Now “[y]ou can take a daily pill that has a good chance of driving your cancer into remission–normalizing your blood count with few, if any, side effects. The new medicine targets CML on a molecular level, so it affects only the enzyme responsible for the disease. The tremendous effectivenss and precision of the approach is heralded as the ‘wave of the future.'”

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Baseline lung cancer screening would lead to more than 130,000 additional survivors in 2012.  
  • Close to one third of all drugs currently in the biopharmaceutical pipeline are for cancer, with around 5,500 potential first-in-class cancer medicines in development.  
  • Low dose CT screening for lung cancer costs less than $200 per person, and surgery for stage I lung cancer is less than 1/2 the cost of late-stage treatment.  
  • A modest decrease of 1% in cancer mortality has been estimated to be worth $500 billion in social value.  
  • Surgical biopsy for lumps in the breast was found by one study to cost 2 1/2 to 3 times more than image-guided core-needle biopsy ($698 versus $243).